Autoantibodies occur in many different nervous system disorders, and are increasingly being found in disorders not traditionally associated with the immune system. Determining if the autoantibodies play a functional or pathogenic role is critical in selecting the most appropriate treatment options.
Immunotherapy for mild cognitive impairment patients: a role for omega-3 fatty acids in improving innate immunity against amyloid-beta
Milan Fiala and Matteo Pellegrini review current research that indicates a role for omega-3 fatty acids in slowing the progression of mild cognitive impairment.
In this edition of NCTalks, we speak to Robyn Klein as part of our Spotlight on neuroimmunology – Robyn discusses her research, how inflammatory processes contribute to neurologic disease, and whether immunology and inflammation could be the basis of an eventual preventative treatment for neurodegenerative disease.
Karmakar & Reilly review what is known about the role of NF1 mutation in immune cell function & the role of immune cells in promoting tumorigenesis in NF1.
In this interview, Dr Akassoglou discusses her pioneering research, as well as the key challenges in this exciting area of neuroscience and her hopes for the field.
Researchers have identified a dysfunctional cell receptor in the immune system that could be part of the cause of chronic fatigue syndrome.
In the quest to cross the BBB, researchers have developed immunoliposomes targeted to BBB receptors and α-synuclein that could potentially enable the transport of drugs to reach one of the drug targets in Parkinson’s disease.
Immune-brain relationships: new paradigms in searching for treatments for neurodegenerative disease?
A systemic immune network involving benign autoimmune T cells supports brain maintenance, function and repair, and could be boosted in a well-controlled manner for therapy of brain pathologies.
Immunotherapy for glioblastoma has been an area of intense research in recent years – this review looks at the potential of HCMV in the initiation, promotion and progression of tumorigenesis.
For the first time, researchers describe the pathological features of a severe liver-injury associated with the administration of the anti–PD-1 agent nivolumab in a patient with glioblastoma.